The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

Cancer Research

Volumn 68, Issue 12, 2008, Pages 4754-4762

  Heckman, Caroline A ^a   Holopainen, Tanja ^a   Wirzenius, Maria ^a   Keskitalo, Salla ^a   Jeltsch, Michael ^a   Ylä Herttuala, Seppo ^b   Wedge, Stephen R ^c   Jürgensmeier, Juliane M ^c   Alitalo, Kari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEDIRANIB; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; 4 ((4 FLUORO 2 METHYL 1H INDOL 5 YL)OXY) 6 METHOXY 7 (3 (PYRROLIDIN 1 YL)PROPOXY)QUINAZOLINE; 4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-(3-(PYRROLIDIN-1-YL)PROPOXY)QUINAZOLINE; ANGIOGENESIS INHIBITOR; QUINAZOLINE DERIVATIVE; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER INHIBITION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; ADENOVIRUS; ANIMAL; CELL MEMBRANE PERMEABILITY; CELL MOTION; CYTOLOGY; DRUG EFFECT; GENETICS; IMMUNOPRECIPITATION; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PHOSPHORYLATION; PHYSIOLOGY; SKIN; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CELL MEMBRANE PERMEABILITY; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOPRECIPITATION; LYMPHANGIOGENESIS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; QUINAZOLINES; SIGNAL TRANSDUCTION; SKIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 49649083397     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5809     Document Type: Article

References (52)

1. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
2. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002;2:573-83.
3. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005;438: 946-53.
4. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-71.
5. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003;28:488-94.
6. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006;312:549-60.
7. Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998;282:946-9.
8. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase FLT4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 1995; 92:3566-70.
9. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006;290:H547-59.
10. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-76.
11. Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 1999;86:2406-12.
12. Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999;154:1381-90.
13. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9 Suppl 1: 2-10.
14. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-8.
15. Boyer SJ. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. Curr Top Med Chem 2002;2:973-1000.
16. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-400.
17. Maris J, Courtright J, Houghton P, et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:581-7.
18. Goodlad RA, Ryan AJ, Wedge SR, et al. Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis 2006;27:2133-9.
19. Smith NR, James NH, Oakley I, et al. Acute pharmacodynamic and anti-vascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther 2007;6:2198-208.
20. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral VEGF signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25:3045-53.
21. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
22. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF) preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 1998;273: 31273-82.
23. Joukov V, Kumar V, Sorsa T, et al. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem 1998;273:6599-602.
24. Kozaki K, Miyaishi O, Tsukamoto T, et al. Establishment and characterization of a human lung cancer cell line NCI-H460-35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. Cancer Res 2000;60:2535-40.
25. He Y, Rajantie I, Pajusola K, et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 2005;65:4739-46.
26. Karpanen T, Heckman CA, Keskitalo S, et al. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J 2006;20:1462-72.
27. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003;161:1163-77.
28. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 2002;8:751-5.
29. Mäkinen T, Veikkola T, Mustjoki S, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 2001;20:4762-73.
30. Shields JD, Emmett MS, Dunn DB, et al. Chemokine-mediated migration of melanoma cells towards lymphatics-a mechanism contributing to metastasis. Oncogene 2007;26:2997-3005.
31. Laitinen M, Zachary I, Breier G, et al. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther 1997;8:1737-44.
32. Puumalainen AM, Vapalahti M, Agrawal RS, et al. β-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 1998;9: 1769-74.
33. Saaristo A, Veikkola T, Tammela T, et al. Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med 2002;196:719-30.
34. Enholm B, Karpanen T, Jeltsch M, et al. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res 2001; 88:623-9.
35. Wirzenius W, Tammela T, Uutela M, et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med 2007;204: 1431-40.
36. Saaristo A, Veikkola T, Enholm B, et al. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J 2002;16:1041-9.
37. Tammela T, Saaristo A, Lohela M, et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 2005;105:4642-8.
38. Karpanen T, Wirzenius M, Makinen T, et al. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. Am J Pathol 2006;169:708-18.
39. Petrova TV, Makinen T, Makela TP, et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J 2002;21:4593-9.
40. Veikkola T, Lohela M, Ikenberg K, et al. Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function. FASEB J 2003; 17:2006-13.
41. He Y, Kozaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002;94:819-25.
42. Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S, Chayama K. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 2004;95:32-9.
43. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-8.
44. Roberts N, Kloos B, Cassella M, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006;66:2650-7.
45. Laakkonen P, Waltari M, Holopainen T, et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 2007;67:593-9.
46. Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 1997;16:3898-911.
47. McColl BK, Paavonen K, Karnezis T, et al. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. FASEB J 2007;21:1088-98.
48. Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 2002; 196:1497-506.
49. Hong YK, Lange-Asschenfeldt B, Velasco P, et al. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the α1β1 and α2β1 integrins. FASEB J 2004;18:1111-3.
50. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002;39:225-37.
51. Vogel C, Bauer A, Wiesnet M, et al. Flt-1, but not Flk-1 mediates hyperpermeability through activation of the PI3-K/Akt pathway. J Cell Physiol 2007;212:236-43.
52. Whittles CE, Pocock TM, Wedge SR, et al. ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Microcirculation 2002;9:513-22.